Year Founded
2017
Ownership
Private
Employees
~50
Therapeutic Areas
Infectious DiseasesNeurology
Stage
Preclinical
Modalities
Small molecule

biotx.ai General Information

Company uses AI-driven causal modeling to predict drug efficacy and has out-licensed six drug assets. Their platform analyzes human genetic data for drug discovery and development.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Potsdam, Brandenburg
Germany

Drug Pipeline

No pipeline data available

For full access to biotx.ai's pipeline data

Book a demo

Key Partnerships

Simbec-Orion

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

biotx.ai Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view biotx.ai's complete valuation and funding history, request access »

biotx.ai Investors

Hoxton Ventures
Investor Type: Venture Capital
Holding: Minority
Stevenage Bioscience Catalyst
Investor Type: Venture Capital
Holding: Minority
Merck Accelerator
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 6 investors. Get the full list »